Refractory Tumor clinical trials at University of California Health

1 in progress, 0 open to eligible people

STI-6643 in Subjects With Advanced Solid Tumors
Sorry, not currently recruiting here
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
at UCSD

Last updated: January 2023